File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Breast conserving surgery in BRCA mutation carriers - a systematic review

TitleBreast conserving surgery in BRCA mutation carriers - a systematic review
Authors
KeywordsBreast neoplasms
Mastectomy
Mastectomy
segmental
Hereditary Breast and Ovarian Cancer Syndrome
Issue Date2019
PublisherElsevier Inc. The Journal's web site is located at http://www.clinical-breast-cancer.com
Citation
Clinical Breast Cancer, 2019, Epub on 2019-08-22 How to Cite?
AbstractIntroduction: Like mastectomy, breast conserving surgery (BCS) is currently the gold standard of surgical treatment for breast cancers in sporadic patients. However, its oncologic safety in BRCA mutation carriers remain controversial; Here we conduct a systematic review to critically evaluate the best evidence from the literature Methods: A comprehensive review was performed on Medline, EMBASE, CINAHL and Cochrane databases using predefined strategy. Retrieved studies were independently screened and rated for relevance. Data were extracted for qualitative synthesis according to the PRISMA protocol for systematic reviews. Results: There is no randomized controlled trial that directly compares BCS and mastectomy in BRCA mutation carriers. Out of the 18 studies included in this review, pooled analysis of overall survival (OS) at 5-, 10- and 15-year were comparable between BCS and mastectomy [88.7%, 89.0% and 83.6% in BCS; comparing to 83%, 86.0% and 83.2%, in mastectomy. However, the pooled ipsilateral breast cancer recurrence rates at 5-, 10- and 15- year were higher in the BCS group at 8.2%, 15.5% and 23%; comparing to that of mastectomy at 3.4%, 4.9% and 6.4%. Conclusion: BCS is associated with higher ipsilateral breast cancer recurrence in BRCA mutation carriers. However, it is not associated with adverse short and long-term survival outcomes. BCS should be offered as an option to BRCA mutation carriers with proper pre-operative counselling.
Persistent Identifierhttp://hdl.handle.net/10722/280253
ISSN
2017 Impact Factor: 2.703
2015 SCImago Journal Rankings: 1.030

 

DC FieldValueLanguage
dc.contributor.authorCo, M-
dc.contributor.authorLiu, T-
dc.contributor.authorLeung, J-
dc.contributor.authorLi, CH-
dc.contributor.authorTse, T-
dc.contributor.authorWong, M-
dc.contributor.authorKwong, A-
dc.date.accessioned2020-01-21T11:50:48Z-
dc.date.available2020-01-21T11:50:48Z-
dc.date.issued2019-
dc.identifier.citationClinical Breast Cancer, 2019, Epub on 2019-08-22-
dc.identifier.issn1526-8209-
dc.identifier.urihttp://hdl.handle.net/10722/280253-
dc.description.abstractIntroduction: Like mastectomy, breast conserving surgery (BCS) is currently the gold standard of surgical treatment for breast cancers in sporadic patients. However, its oncologic safety in BRCA mutation carriers remain controversial; Here we conduct a systematic review to critically evaluate the best evidence from the literature Methods: A comprehensive review was performed on Medline, EMBASE, CINAHL and Cochrane databases using predefined strategy. Retrieved studies were independently screened and rated for relevance. Data were extracted for qualitative synthesis according to the PRISMA protocol for systematic reviews. Results: There is no randomized controlled trial that directly compares BCS and mastectomy in BRCA mutation carriers. Out of the 18 studies included in this review, pooled analysis of overall survival (OS) at 5-, 10- and 15-year were comparable between BCS and mastectomy [88.7%, 89.0% and 83.6% in BCS; comparing to 83%, 86.0% and 83.2%, in mastectomy. However, the pooled ipsilateral breast cancer recurrence rates at 5-, 10- and 15- year were higher in the BCS group at 8.2%, 15.5% and 23%; comparing to that of mastectomy at 3.4%, 4.9% and 6.4%. Conclusion: BCS is associated with higher ipsilateral breast cancer recurrence in BRCA mutation carriers. However, it is not associated with adverse short and long-term survival outcomes. BCS should be offered as an option to BRCA mutation carriers with proper pre-operative counselling.-
dc.languageeng-
dc.publisherElsevier Inc. The Journal's web site is located at http://www.clinical-breast-cancer.com-
dc.relation.ispartofClinical Breast Cancer-
dc.subjectBreast neoplasms-
dc.subjectMastectomy-
dc.subjectMastectomy-
dc.subjectsegmental-
dc.subjectHereditary Breast and Ovarian Cancer Syndrome-
dc.titleBreast conserving surgery in BRCA mutation carriers - a systematic review-
dc.typeArticle-
dc.identifier.emailCo, M: mcth@hku.hk-
dc.identifier.emailKwong, A: avakwong@hku.hk-
dc.identifier.authorityCo, M=rp02101-
dc.identifier.authorityKwong, A=rp01734-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.clbc.2019.07.014-
dc.identifier.hkuros308967-
dc.identifier.volumeEpub on 2019-08-22-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats